G01N 2333/5434
Il-12
G01N2333/5434 (Il-12) appears on 30 US grants and 83 published applications in this corpus.
Search patents in G01N- Granted patents
- 30
- Published applications
- 83
- Assignees
- 56
- Inventors
- 191
- Latest grant
- 30 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 2 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 3 |
| 2012 | 0 | 2 |
| 2013 | 0 | 1 |
| 2014 | 1 | 4 |
| 2015 | 1 | 6 |
| 2016 | 2 | 6 |
| 2017 | 4 | 11 |
| 2018 | 2 | 6 |
| 2019 | 2 | 5 |
| 2020 | 4 | 5 |
| 2021 | 3 | 6 |
| 2022 | 1 | 7 |
| 2023 | 1 | 1 |
| 2024 | 3 | 5 |
| 2025 | 3 | 6 |
| 2026 | 3 | 7 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Cytokine-based therapies and methods30 Jun 2026US 12,668,627 B2Reverb Therapeutics, Inc.
- Anti-human P40 protein domain antibody and use thereof7 Apr 2026US 12,595,300 B2Akeso Biopharma, Inc.
- Methods of detecting and treating cerebral aneurysms17 Feb 2026US 12,553,904 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Cytokines and use thereof9 Dec 2025US 12,492,235 B2The Catholic University of Korea Foundation Industry-Academic Cooperation
- Biomarkers related to organ function25 Mar 2025US 12,259,397 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Novel cytokine-based therapies and methods17 Sep 2026US 2026/0274943 A1Reverb Therapeutics, Inc.
- Anti-Human P40 Protein Domain Antibody And Use Thereof30 Jul 2026US 2026/0217813 A1Akeso Biopharma, Inc.
- Systemic biomarkers for the dynamic assessment of tumor burden and treatment efficacy in high grade gliomas2 Jul 2026US 2026/0188489 A1Mary Hitchcock Memorial Hospital, for itself and on behalf of Dartmouth-Hitchcock Clinic
- Compositions of anti-interleukin 12/interleukin 23 antibody25 Jun 2026US 2026/0176330 A1Amgen Inc.
- Use of monolithic anion exchange chromatography and light scattering for quantifying extracellular vesicles7 May 2026US 2026/0124150 A1Lonza Sales AG
Most cited
By later US patents
- Vagus nerve stimulation pre-screening test17US 11,173,307 B2SetPoint Medical Corporation · 2021
- Methods and compositions for diagnosis and prognosis of renal injury and renal failure15US 8,993,250 B2Astute Medical, Inc. · 2015
- Methods for prediction of anti-TNFα drug levels and autoantibody formation12US 10,571,467 B2Prometheus Biosiences, Inc. · 2020
- Atypical hemolytic uremic syndrome (AHUS) biomarker proteins11US 9,494,601 B2Alexion Pharmaceuticals, Inc. · 2016
- Atypical hemolytic uremic syndrome (aHUS) biomarker proteins8US 9,658,236 B2Alexion Pharmaceuticals, Inc. · 2017